68 related articles for article (PubMed ID: 3323023)
41. A trial of verapamil in the treatment of stuttering in adults.
Brady JP; Price TR; McAllister TW; Dietrich K
Biol Psychiatry; 1989 Mar; 25(5):630-3. PubMed ID: 2645943
[No Abstract] [Full Text] [Related]
42. Treatment of schizophrenia with verapamil.
Price WA; Pascarzi G; Giannini AJ
J Clin Psychopharmacol; 1986 Aug; 6(4):249. PubMed ID: 3734147
[No Abstract] [Full Text] [Related]
43. [Clinical use of a portable microcomputerized diagnostic system].
Zheng YP
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1987 Apr; 20(2):84-6. PubMed ID: 3304872
[No Abstract] [Full Text] [Related]
44. Haloperidol metabolism and antipsychotic effect in schizophrenia.
Altamura AC; Mauri MC; Cavallaro R; Gorni A
Lancet; 1987 Apr; 1(8536):814-5. PubMed ID: 2882227
[No Abstract] [Full Text] [Related]
45. Verapamil in stuttering.
Brady JP; McAllister TW; Price TR
Biol Psychiatry; 1990 Mar; 27(6):680-1. PubMed ID: 2182135
[No Abstract] [Full Text] [Related]
46. Commentary: CRP and schizophrenia: cause, consequence or confounding?
Ligthart S
Int J Epidemiol; 2019 Oct; 48(5):1514-1515. PubMed ID: 31578548
[No Abstract] [Full Text] [Related]
47. Calcium channel blockers for antipsychotic-induced tardive dyskinesia.
Essali A; Soares-Weiser K; Bergman H; Adams CE
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD000206. PubMed ID: 29578611
[TBL] [Abstract][Full Text] [Related]
48. From Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms.
Kabir ZD; MartÃnez-Rivera A; Rajadhyaksha AM
Neurotherapeutics; 2017 Jul; 14(3):588-613. PubMed ID: 28497380
[TBL] [Abstract][Full Text] [Related]
49. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.
Lencz T; Malhotra AK
Mol Psychiatry; 2015 Jul; 20(7):820-6. PubMed ID: 25869805
[TBL] [Abstract][Full Text] [Related]
50. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
Krystal JH; D'Souza DC; Mathalon D; Perry E; Belger A; Hoffman R
Psychopharmacology (Berl); 2003 Sep; 169(3-4):215-33. PubMed ID: 12955285
[TBL] [Abstract][Full Text] [Related]
51. Dealing with sadness, madness and hostility. New psychotropic drug remedies for the future.
Loonen AJ
Pharm Weekbl Sci; 1992 Aug; 14(4A):206-20. PubMed ID: 1437502
[TBL] [Abstract][Full Text] [Related]
52. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
53. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Abuzzahab FS; Zimmerman RL
J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
[TBL] [Abstract][Full Text] [Related]
54. Verapamil in the treatment of schizophrenia.
Wells BG
DICP; 1990 Sep; 24(9):838-40. PubMed ID: 2260342
[No Abstract] [Full Text] [Related]
55. Antipsychotic effects of verapamil in schizophrenia.
Price WA
Hillside J Clin Psychiatry; 1987; 9(2):225-30. PubMed ID: 3323023
[TBL] [Abstract][Full Text] [Related]
56. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
57. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial.
Akhondzadeh S; Nejatisafa AA; Amini H; Mohammadi MR; Larijani B; Kashani L; Raisi F; Kamalipour A
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):1007-12. PubMed ID: 14499318
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
